Patent · US Expired

Enantioselective enzymatic aminolysis of a racemic 2-isoxazolylacetate alkyl ester

US6624311B2 · kind B2 · utility

2Cited by

1References

17Claims

0Family size

Assignee

Bristol-Myers Squibb Pharma Company · US

Inventors

Robert DiCosimo · Chadds Ford, US
Philip Ma · Mountain View, US
Jaan A. Pesti · Yardley, US

Key dates

Filing date	Oct 25, 2001
Grant date	Sep 23, 2003
Priority date	—
Expiry date	Oct 25, 2021

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12P17/14
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The present invention relates to a process for the enantioselective enzymatic aminolysis of racemic 2-[3-(4-cyanophenyl)-4,5-dihydro-5-isoxazolyl]acetate ((R/S)-I) by methyl N&agr;-Boc-L-&agr;,&bgr;-diaminoproprionate.p-toluenesulfonic acid. More specifically, this invention pertains to a process for the enantioselective enzymatic aminolysis of racemic isobutyl 2-[3-(4-cyanophenyl)-4,5-dihydro-5-isoxazolyl]-acetate by methyl N&agr;-Boc-L-&agr;,&bgr;-diaminoproprionate.p-toluene sulfonic acid to produce (R)-methyl-3-[[[3-(4-cyanophenyl)-4,5-dihydro-5-isoxazolyl]acetyl]amino]-N-(butoxycarbonyl)-L-alanine, an intermediate in the preparation of roxifiban, an isoxazoline-based platelet glycoprotein IIb/IIIa antagonist which has activity as an antithrombotic agent.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.